IndiaThe UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has reported nearly 200 deaths linked to the use of GLP-1 weight-loss drugs like Mounjaro, Wegovy, and Ozempic, along with over 150,000 adverse reactions. These figures come from the MHRA Yellow Card scheme, where healthcare professionals, the public, and pharmaceutical companies can report side effects. While the MHRA emphasizes that these reports do not confirm causation, they highlight potential risks. Most adverse reactions were gastrointestinal issues, with some cases involving cardiac and psychiatric disorders. Specific examples include the death of Caroline Savage, who died after increasing her Mounjaro dose, and Paula Owen, whose death was partially attributed to GLP-1 medication.
Bias read (Center): The article presents statistical data from the MHRA without overtly favoring any particular perspective. It includes both the number of reported incidents and the MHRA’s cautionary statement that correlation does not imply causation. The tone remains factual and balanced, avoiding strong advocacy or
